[1] 国家药典委员会. 中华人民共和国药典: 一部[S]. 北京: 中国医药科技出版社, 2020: 372.
[2] 李春, 孙玉茹, 孙有富. 中药路路通化学成分的研究[J]. 药学学报, 2002(04): 263-266.
[3] 商洪杰, 王文静, 李丹毅, 等. 路路通中1个新的三萜类化合物[J]. 中草药, 2014, 45(09): 1207-1210.
[4] 杨欣欣, 张云坤, 王帅, 等. 不同产地路路通体外抗肝癌作用及谱效关系[J]. 中成药, 2021, 43(7): 1799-1804.
[5] 穆晓婷, 钱平, 将璐璐, 等. 路路通酸对乳腺癌MCF-7细胞和宫颈癌C-33A细胞增殖的影响[J]. 实用药物与临床, 2017, 20(03): 254-257.
[6] 张秀娟, 李宏伟, 季宇彬, 等. 桦木酮酸对肿瘤细胞SGC-7901、HepG-2及S180荷瘤小鼠肿瘤细胞的影响[J]. 天然产物研究与开发, 2009, 21(05): 766-770.
[7] 张秀娟, 李国媛, 季宇彬, 等. 桦木酮酸对人肝癌细胞及对动物移植性肿瘤H22细胞的影响[J]. 林产化学与工业, 2009, 29(01): 46-50.
[8] 封若雨, 朱新宇, 刑峰丽, 等. 路路通的药理作用研究概述[J]. 中国中医基础医学杂志, 2019, 25(08): 1175-1178.
[9] 庄延双, 蔡宝昌, 张自力. 网络药理学在中药研究中的应用进展[J]. 南京中医药大学学报, 2021, 31(1): 156-160.
[10] 陈海彬, 周红光, 李文婷, 等. 网络药理学——中药复方作用机制研究新视角[J]. 中华中医药杂志, 2019, 34(7): 2873-2876.
[11] 但文超, 刘红旭, 何庆勇, 等. 基于网络药理学与分子对接方法探讨黄山药干预冠心病的作用机制研究[J]. 世界科学技术—中医药现代化, 2021, 23(6): 1830-1843.
[12] JIAO X Y, JIN X, MA Y Y, et al. A comprehensive application: Molecular docking and network pharmacology for the prediction of bioactive constituents and elucidation of mechanisims of action in component-based Chinese medicine[J]. Comput Biol Chem, 2021, 90: 107402. doi:  10.1016/j.compbiolchem.2020.107402
[13] 刘金垒, 但文超, 何庆勇, 等. 基于网络药理学的地榆升白片对白细胞减少症的作用机制研究[J]. 中国现代中药, 2020, 22(09): 1494-1501.
[14] LI J S, ZHAO P, LI Y, et al. Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease[J]. Sci Rep, 2015, 5: 15290. doi:  10.1038/srep15290
[15] TROTT O, OLSON A J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading[J]. J Comput Chem, 2010, 31(2): 455-461. doi:  10.1002/jcc.21334
[16] HISIN KY, GHOSH S, KITANO H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology[J]. PLoS One, 2013, 8(12): e83922. doi:  10.1371/journal.pone.0083922
[17] 李沐涵, 殷美琦, 冯靖涵, 等. 没食子酸抗肿瘤作用研究进展[J]. 中医药信息, 2011, 28(1): 109-111.
[18] 王少墨, 王庆其. 络脉理论与肿瘤临床运用刍议[J]. 浙江中医杂志, 2012, 47(3): 157-159.
[19] 王金辉, 周婷, 祝慧芳. 经络与肿瘤关系的研究进展[J]. 江西中医药, 2016, 47(06): 77-80.
[20] ZHOU M, LIU X J, LI Z H, et al. Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells[J]. Int J Cancer, 2018, 143(4): 921-930. doi:  10.1002/ijc.31374
[21] YOUSEFNIA S, MOMENZADEH S, SEYED FOROOTAN F, et al. The influence of peroxisome proliferator-activated receptor γ(PPARγ) ligands on cancer cell tumorigenicity[J]. Gene, 2018, 649: 14-22. doi:  10.1016/j.gene.2018.01.018
[22] 22 DUSTIN D, GU G W, FUQUA S A W. ESR1 mutations in breast cancer[J]. Cancer, 2019, 125(21): 3714-3728. doi:  10.1002/cncr.32345
[23] 23 UR RAHMAN M S, CAO J. Estrogen receptors in gastric cancer: Advances and perspectives[J]. World J Gastroenterol, 2016, 22(8): 2475-2482. doi:  10.3748/wjg.v22.i8.2475
[24] YANG Q, JIANG W, HOU P. Emerging role of PI3K/AKT in tumor-related epigenetic regulation[J]. Semin Cancer Biol, 2019, 59: 112-124. doi:  10.1016/j.semcancer.2019.04.001
[25] XUE C, LI G L, LU J, et al. Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression[J]. Signal Transduct Target Ther, 2021, 6(1): 400. doi:  10.1038/s41392-021-00788-w
[26] HUANG J. Current developments of targeting the p53 signaling pathway for cancer treatment[J]. Pharmacol Ther, 2021, 220: 107720. doi:  10.1016/j.pharmthera.2020.107720
[27] 27 HASHEMI GORADEL N, NAJAFI M, SALEHI E, et al. Cyclooxygenase-2 in cancer: A review[J]. J Cell Physiol, 2019, 234(5): 5683-5699. doi:  10.1002/jcp.27411
[28] ZAHEDI T, HOSSEINZADEH COLAGAR A, MAHMOODZADEH H. PTGS2 Over-Expression: A colorectal Carcinoma Initiator not an Invasive Factor[J]. Rep Biochem Mol Biol, 2021, 9(4): 442-451.
[29] VILLA A L P, PARRA R S, FEITOSA M R, et al. PPARG expression in colorectal cancer and its association with staging and clinical evolution[J]. Acta Cir Bras, 2020, 35(7): e202000708. doi:  10.1590/s0102-865020200070000008
[30] 吴亚玲, 万海栗, 邹心怡, 等. 基于网络药理学及分子对接探究六君子治疗结直肠癌的作用机制[J]. 中医临床研究, 2023, 15(20): 16-24.